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A B S T R A C T
Hemoglobin-based oxygen carriers (HBOCs) are an investigational replacement for blood transfusions and are
known to cause oxidative damage to tissues. To investigate the correlation between their oxygen binding
properties and these detrimental eﬀects, we investigated two PEGylated HBOCs endowed with diﬀerent oxygen
binding properties - but otherwise chemically identical - in a Guinea pig transfusion model. Plasma samples were
analyzed for biochemical markers of inﬂammation, tissue damage and organ dysfunction; proteins and lipids of
heart and kidney extracts were analyzed for markers of oxidative damage. Overall, both HBOCs produced higher
oxidative stress in comparison to an auto-transfusion control group. Particularly, tissue 4-hydro-
xynonenal adducts, tissue malondialdehyde adducts and plasma 8-oxo-2'-deoxyguanosine exhibited signiﬁcantly
higher levels in comparison with the control group. For malondialdehyde adducts, a higher level in the renal
tissue was observed for animals treated with the high-aﬃnity HBOC, hinting at a correlation between the HBOCs
oxygen binding properties and the oxidative stress they produce. Moreover, we found that the high-aﬃnity
HBOC produced greater tissue oxygenation in comparison with the low aﬃnity one, possibly correlating with the
higher oxidative stress it induced.
1. Introduction
Hemoglobin-based oxygen carriers (HBOCs) have been investigated
for more than 40 years as possible substitutes for whole blood trans-
fusions. HBOCs are based on cell-free hemoglobin (Hb) that has un-
dergone either chemical or genetic modiﬁcations to increase its reten-
tion in the bloodstream while maintaining the capability to deliver
oxygen to tissues [1–4]. They include Hbs conjugated with bulky
polymers [5–9], cross-linked and/or polymerized Hbs [10–12], and
encapsulated Hbs [13–16]. HBOCs exhibit a wide range of biochemical
and biophysical properties [17].
Conjugation of puriﬁed Hb with polyethylene glycol (PEG) has
emerged as a particularly promising approach for the design of HBOCs
[5–9,18–27]. However, PEGylation of Hb under aerobic conditions
signiﬁcantly alters its structural and functional properties, promoting
tetramer dissociation, increasing oxygen aﬃnity and abolishing oxygen
binding cooperativity [27–29]. Indeed, the aerobically PEGylated Hb
known as MP4, Hemospan or MP4OX (Sangart, San Diego, CA, USA),
the ﬁrst of these products to reach phase 2 clinical trials, exhibited a
p50 close to that of R-state Hb, with minimal cooperativity in oxygen
binding [5,22,30–32], mostly a consequence of Hb dimerization
[28,33,34]. PEGylation with the same chemistry but under anaerobic
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conditions led to a low-aﬃnity HBOC, named Euro-PEG-Hb [9], which,
in contrast to MP4, maintained cooperativity in oxygen binding. It did
not produce profound hypertension in a rat model and was 99% re-
tained in the plasma within 6 h [9]. Despite the availability of Hb PEG-
derivatives endowed with widely diﬀerent oxygen binding properties, it
is still debated whether an oxygen aﬃnity close to that of RBCs is al-
ways desirable. Particularly, the extremely low oxygen tensions that
can be reached in ischemic tissues might call for high-aﬃnity HBOCs to
optimize oxygen delivery where it is most needed [35].
There is evidence that most, if not all, currently available HBOCs
tend to produce, besides vasoconstriction and hypertension [36], oxi-
dative-stress, particularly at the level of the myocardium [37,38] and of
the kidneys [39]. These eﬀects in humans were shown to be poorly
predicted by mouse and rat models, mainly because of a diﬀerent
armory of plasma reducing agents, hampering pre-clinical investigation
and leading to disappointing clinical trials [40]. It was suggested that
Cavia porcellus (Guinea pig), which, as humans and unlike rats and
mice, lacks of endogenous ascorbic acid, could lead to a better pre-
diction of the eﬀects of HBOCs in humans [41,42]. Consistently, Guinea
pigs or knockout mice not capable of ascorbate synthesis were proposed
for the testing of HBOCs [41].
Previous comparisons among HBOCs with diﬀerent oxygen binding
p50 led to the suggestion that hemodynamic eﬀects are related to
oxygen binding properties [35]. However, these studies used chemi-
cally distinct HBOCs and did not assess in vivo toxicity. In order to
understand whether diﬀerent oxygen binding properties of otherwise
similar products aﬀect the oxidative stress and to identify markers of
oxidative stress that could be detected days after transfusion, we pre-
pared a high- and a low-oxygen aﬃnity PEGylated Hb with the same
modiﬁcation chemistry and we tested them in a Guinea pig model of
transfusion. PEG-Hboxy, a MP4 [5,22] mimic, and PEG-Hbdeoxy, an
anaerobically-PEGylated Hb, have already been compared from a bio-
chemical point of view [28]. Oxidative stress markers were assessed in
plasma and in protein extracts from heart and kidney.
2. Materials and methods
2.1. Materials
Chemicals were of the best commercial quality available. MAL-PEG
was purchased from Iris Biotech GmbH (Marktredwitz, Germany).
Immunochemical assays were purchased from Merck Millipore
(Darmstadt, Germany), Cell Biolabs (San Diego, CA, USA) or Cayman
Chemical (Ann Arbor, MI, USA), as speciﬁed for each marker. All other
products were purchased from Sigma-Aldrich (St. Louis, MO, USA),
unless otherwise stated.
2.2. Human hemoglobin puriﬁcation
An aliquot of 45mL of human whole blood was added to two vo-
lumes of endotoxin-free water for red blood cells (RBCs) lysis. The RBC
ghosts were separated by addition of solid NaCl (5% w/v) followed by
centrifugation at 38000 rpm for 1 h. The resulting Hb solution was
ﬁlter-sterilized (0.2 µm), dialyzed extensively against the appropriate
buﬀer (depending on the conjugation protocol, vide infra) and con-
centrated to 2.5 mM using a 50 kDa cutoﬀ tangential ﬂow membrane
(Repligen, Waltham, MA, USA). All the operations were carried out in
sterilized glassware and centrifuge tubes previously washed with
caustic soda and rinsed with endotoxin-free water. All reagents stock
solutions and buﬀers were prepared by dissolving the powders in sterile
water for parental use. Hb concentration at all steps was assessed by
UV–visible absorption using a Cary 4000 UV–VIS spectrophotometer
(Agilent Technologies, Santa Clara, CA, USA).
2.3. HBOCs preparation
For the preparation of both PEG-Hbdeoxy and PEG-Hboxy, Hb con-
jugation with PEG was carried out in a two-step procedure that in-
volved: i) thiolation with iminothiolane (IMT) and ii) PEGylation with
maleimido-functionalized PEG (MAL-PEG).
For PEG-Hbdeoxy, PEG conjugation was carried out under anaerobic
conditions in the presence of inositol hexaphosphate (IHP), as already
described [28]. The reaction was carried out in a buﬀered solution
containing 50mM sodium phosphate, 100mM KCl, 0.5 mM EDTA, pH
7.0, in a 1 L bottle ﬂuxed with ﬁlter-sterilized nitrogen, at 20 °C, to
which deoxygenated solutions of reagents were added anaerobically.
Before PEG conjugation, IHP (1.2 IHP/tetramer ratio) was added to the
Hb sample (0.6 mM on tetramer basis). Hb was then reacted with IMT
(80mol/tetramer mol) and, after 1.5 min, with 5 kDa MAL-PEG
(12mol/tetramer mol). The addition of a lysine-containing solution
after 25min and a cysteine-containing solution after 30min blocked
IMT and MAL-PEG reactions, respectively. The sample was dialyzed
against phosphate buﬀer saline (PBS) and concentrated by using a
50 kDa cutoﬀ tangential ﬂow membrane, under aerobic conditions, in
order to eliminate unreacted MAL-PEG and other reagents. Finally, the
protein sample was passed through a 0.2 µm syringe ﬁlter and spun
through Proteus NoEndo spin columns (Charles River Laboratories,
Wilmington, MA, USA) for endotoxin removal. After the conjugation
reaction, PEG-Hbdeoxy at 1.64mM concentration was obtained and
stored at −80 °C.
For PEG-Hboxy, PEG conjugation was carried out aerobically, in the
same reaction conditions reported for MP4 (Hemospan, Sangart, USA)
[5]. The reaction was carried out in a 1 L bottle at 4–5 °C. Hb (3mM on
heme basis) was treated with IMT (10mol/tetramer mol) in PBS buﬀer,
pH 7.4 for 4 h before the addition of MAL-PEG (20mol/tetramer mol).
After 2 h of incubation under the same conditions, the PEGylation re-
action was terminated by the addition of a cysteine-containing solution
(6mol/MAL-PEG mol). The sample was then dialyzed against PBS and
concentrated under aerobic conditions by using a 50 kDa cutoﬀ tan-
gential ﬂow membrane in order to eliminate unreacted MAL-PEG and
other reagents. Finally, the protein sample was passed through a 0.2 µm
syringe ﬁlter and spun through Proteus NoEndo spin columns (Charles
River Laboratories, Wilmington, MA, USA) for endotoxin removal. After
the conjugation reaction, PEG-Hboxy at 1.69mM concentration was
obtained and stored at −80 °C.
2.4. Characterization of PEG-Hboxy and PEG-Hbdeoxy oxygen binding
properties and purity
Oxygen binding properties and met-Hb content were assessed as
already described [3]. Purity, degree of PEGylation and distribution of
PEGylated monomers were assessed by image analysis of SDS-PAGE
gels, as already described [28].
2.5. Quantiﬁcation of endotoxins
The content of endotoxins in the ﬁnal products was assessed using a
kinetic LAL test (Endochrome-K, Charles River Laboratories,
Wilmington, MA, USA). Five diﬀerent standard dilutions (50–0.005 EU/
mL) were used to produce a log/log correlation of the onset time of
each standard with its corresponding endotoxin concentration. The
standard curve parameters were then used to calculate the endotoxin
levels of the PEG-Hbdeoxy and PEG-Hboxy samples. The positive product
control (spiked samples) consisted of PEG-Hbdeoxy and PEG-Hboxy so-
lutions in which endotoxins were added at concentrations around the
midpoint of the standard curve.
2.6. Animals preparation
Procedures involving animals and their care were performed in
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accordance with institutional guidelines in compliance with national
and international law and policies. The protocol was approved by the
Institutional Animal Care and by the Italian Health Ministry (Legislative
Decree no 76/2014- B).
Twenty-four Hartley Guinea pigs (Charles River Laboratories, Italy)
weighing 458 ± 134 g were housed in speciﬁc pathogen-free condi-
tions with climate control (humidity between 45% and 65%;
temperature between 20 °C and 24 °C), with free access to chow and
water. After one week of acclimatization, Guinea pigs were anesthe-
tized with an intraperitoneal injection of 100mg/kg ketamine
(Imalgene 1000, Material Italia SPA, Italy) and 5mg/kg xylazine
(Sedaxylan 2%, Happyfarma, Italy); additional doses (Ketamine 30mg/
kg and Xylazine 1.5 mg/kg) were administrated when required to
maintain anaesthesia. Under aseptic conditions, a midline incision was
Table 1
Oxygen binding properties of PEG-Hbdeoxy and PEG-Hboxy. p50 and Hill coeﬃcient ( ± SE) of HbA, PEG-Hbdeoxy and PEG-Hboxy, in the absence and presence of 5%
CO2 and 200mM Cl−, in a solution containing 100mM Hepes, 1 mM EDTA, at 15 °C, pH 7.0. The Hb concentration was 110–200 µM.
Sample Stripped +CO2 +Cl- Endotoxin levels (EU/mL) PEG/ tetramer
p50 (torr) n p50 (torr) n p50 (torr) n
HbA 2.61 ± 0.05 2.36 ± 0.06 4.09 ± 0.02 2.70 ± 0.04 5.15 ± 0.01 3.08 ± 0.02
PEG-Hbdeoxya 3.18 ± 0.08 2.54 ± 0.19 3.71 ± 0.03 2.21 ± 0.03 3.66 ± 0.05 2.23 ± 0.06 21 5.7
PEG-Hboxy 0.85 ± 0.02 1.34 ± 0.04 1.23 ± 0.03 1.33 ± 0.06 1.38 ± 0.04 1.44 ± 0.06 14 6.6
a Depending on sample concentration, the formation of a dimeric oxygen binding species was observed, with an apparent tetramer-dimer equilibrium constant of
21.5 ± 2.3 μM [28].
Table 2
Hemodynamic parameters and survival of transfused animals. Data are shown as mean± SD. BL, baseline; PT, post transfusion. Statistical analysis: (A) One-way
ANOVA followed by Tukey's multiple comparisons test, comparison between groups at the same time, * ctrl vs PEG-Hbdeoxy, # ctrl vs PEG-Hboxy. (B) Two-way
ANOVA followed by Sidak's multiple comparisons test, comparison between groups at the same time, * ctrl vs PEG-Hbdeoxy, # ctrl vs PEG-Hboxy.
AT PEG-Hboxy PEG-Hbdeoxy P value summary Statistical analysis
Body weight (g) 401 ± 59 396 ± 86 411 ± 92 ns
Survival (n/n) 5/7 3/8 6/9 ns
Heart rate (beats/min) (A)
BL 213 ± 40 209 ± 24 232 ± 29 ns
Start Transfusion 216 ± 35 212 ± 22 245 ± 30 * *
During Transfusion 190 ± 18 210 ± 6 227 ± 22 * */#
End Transfusion 188 ± 16 221 ± 11 236 ± 29 #
PT 30min 197 ± 18 222 ± 17 218 ± 16 ##
PT 60min 190 ± 13 219 ± 15 206 ± 20 #
PT 120min 197 ± 21 224 ± 16 197 ± 17 ns
Systolic Arterial Pressure (mmHg) (A)
BL 53 ± 9 54 ± 9 55 ± 6 ns
PT 30min 51 ± 12 58 ± 8 49 ± 10 ns
PT 60min 53 ± 8 60 ± 5 60 ± 4 ns
PT 120min 51 ± 12 64 ± 9 56 ± 13 ns
Mean arterial pressure (mmHg) (A)
BL 46 ± 8 44 ± 7 48 ± 6 ns
PT 30min 43 ± 12 52 ± 6 40 ± 10 ns
PT 60min 42 ± 7 52 ± 10 50 ± 5 * /#
PT 120min 41 ± 12 55 ± 8 44 ± 11 ns
Diastolic arterial pressure (mmHg) (A)
BL 38 ± 9 38 ± 7 41 ± 4 ns
PT 30min 36 ± 11 44 ± 5 33 ± 9 ns
PT 60min 36 ± 7 42 ± 7 40 ± 4 ns
PT 120min 35 ± 8 45 ± 8 34 ± 8 ns
pH (B)
BL 7.40 ± 0.03 7.5 ± 0.1 7.42 ± 0.03 ns
PT 120min 7.41 ± 0.02 7.44 ± 0.05 7.42 ± 0.05 ns
pO2 (mmHg) (B)
BL 65 ± 14 67 ± 15 78 ± 19 ns
PT 120min 75 ± 10 78 ± 9 87 ± 10 ns
sO2 (%) (B)
BL 91 ± 4 91 ± 4 93 ± 5 ns
PT 120min 94 ± 3 95 ± 2 97 ± 1 ns
pCO2 (mmHg) (B)
BL 50 ± 7 49 ± 9 47 ± 3 ns
PT 120min 48 ± 4 48 ± 4 45 ± 3 ns
HCO3 (B)
BL 32 ± 5 32 ± 4 31 ± 3 ns
PT 120min 30 ± 4 32 ± 4 29 ± 3 ns
Hct (%PCV) (B)
BL 34 ± 4 38 ± 1 36 ± 2 ns
PT 120min 34 ± 4 26 ± 4 28 ± 4 * */####
Hb (g/dL) (B)
BL 12 ± 1 13 ± 1 12 ± 1 ns
PT 120min 12 ± 1 9 ± 1 9 ± 1 * */####
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made around the neck region, allowing for blunt dissection and ex-
posure of the right common carotid artery and the left external jugular
vein. A PE-50 catheter was advanced into the right common carotid
artery for measurement of the arterial pressure and for blood with-
drawal. Another PE-50 catheter was placed in the left external jugular
vein for blood or HBOC infusion. All of the catheters were ﬂushed in-
termittently with saline containing 2.5 IU/mL of heparin. A conven-
tional lead II electrocardiogram (ECG) was continuously monitored.
Temperature was measured with the aid of a rectal probe and main-
tained at 37 ± 0.5 °C throughout the experiment.
2.7. HBOCs administration
Before surgery, animals were randomized to one of the following
groups: i) control (auto-transfusion, AT), ii) transfusion with PEG-
Hboxy, iii) transfusion with PEG-Hbdeoxy. Fifteen minutes prior to
transfusion, baseline physiological parameters were measured.
Isovolemic transfusion of 9mL of whole blood or HBOC was achieved
by withdrawal of blood from the carotid artery at 6mL/h and the
concomitant administration of PEG-Hboxy or PEG-Hbdeoxy, maintained
at 37 °C, through the jugular vein, at the same rate, using two peristaltic
Fig. 1. Hemodynamic parameters upon HBOC transfusion. (a) Heart rates before and after transfusion with PEG-Hbdeoxy (closed circles) or PEG-Hboxy (gray squares)
in comparison with the auto-transfusion group (open triangles). Data are shown as mean± SD. Statistical analysis: Ordinary one-way ANOVA followed by Tukey's
multiple comparisons test, comparison among groups at the same time point, * ctrl vs PEG-Hbdeoxy, # ctrl vs PEG-Hboxy, § PEG-Hboxy vs PEG-Hbdeoxy. CTRL n=7,
PEG-Hboxy n= 8, PEG-Hbdeoxy n=9. (b) Mean Arterial Pressure before and after transfusion with PEG-Hbdeoxy (closed circles) or PEG-Hboxy (gray squares) in
comparison with the auto-transfusion group (open triangles). Statistical analysis: Ordinary one-way ANOVA followed by Tukey's multiple comparisons test, com-
parison among groups at the same time point, * ctrl vs PEG-Hbdeoxy, # ctrl vs PEG-Hboxy, § PEG-Hboxy vs PEG-Hbdeoxy. CTRL n=7, PEG-Hboxy n= 8, PEG-Hbdeoxy
n= 9. (c) Hematocrit, (d) Hb content and (e) oxygen saturation before (black bars) and after 2 h (gray bars) from transfusion. Data are shown as mean± SD.
Statistical analysis: Two-way ANOVA followed by Sidak's multiple comparisons test,* vs own baseline, # vs 2 h ctrl. Ctrl n=7, PEG-Hboxy n=8, PEG-Hbdeoxy n= 9.
Fig. 2. Western blot of plasma samples pooled from all
animals of each group compared with puriﬁed HBOCs. M.
Molecular weight marker, 1. Puriﬁed PEG-Hboxy, 2.
Plasma pool of animals before transfusion with PEG-Hboxy,
3. Plasma pool of animals after 2 h from transfusion of
PEG-Hboxy, 4. Plasma pool of animals after 7 days from
transfusion of PEG-Hboxy, 5. Puriﬁed PEG-Hbdeoxy, 6.
Plasma pool of animals before transfusion of PEG-Hbdeoxy,
7. Plasma pool of animals after 2 h from transfusion of
PEG-Hbdeoxy, 8. Plasma pool of animals after 7 days from
transfusion of PEG-Hbdeoxy.
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pumps (MINIPLUS 3, Gilson, Middleton, WI, USA). In the control group,
animals were subjected to auto-transfusion. Following isovolemic
transfusion, animals were monitored for 2 h. Plasma was withdrawn for
analyses at baseline and 2 h after the transfusion. Catheters were then
removed and 0.05mg/kg buprenorphine (Temgesic, Torrinomedica,
Italy), was administered subcutaneously. The animals were then re-
turned to their cages and observed for up to 7 days.
2.8. Blood pressure and blood gas analysis
Aortic pressure was measured with reference to the mid chest with
high-sensitivity transducers. Aortic pressure and ECG were con-
tinuously recorded on a computer-based data acquisition system sup-
ported by CODAS hardware and software (DataQ, Akron, OH, USA).
Arterial blood gases and hematocrit were assessed with an i-STAT
System (Abbott Laboratories, Princeton, NJ, USA), at baseline and at 2 h
after transfusion.
2.9. Blood/tissue collection
After seven days, animals were anesthetized as described above and
blood was withdrawn from the abdominal cava vein for biochemical
analyses. Blood was collected into EDTA-vacutainers and centrifuged
for 2min at 12,000 rpm. Plasma samples were stored at − 80 °C.
Fig. 3. Selected plasma analytes: (a) L-lactate concentration, (b) urea concentration, (c) creatinine concentration, (d) LDH activity, (e) GOT activity, (f) cTnT
concentration for the auto-transfusion group (AT) and for animals transfused with PEG-Hboxy and PEG-Hbdeoxy before treatment (BL, black bars), after 2 h from
transfusion (light gray bars) and after 7 days (dark gray bars). Data are shown as mean± SD (a-e) or median± IQR (f). Statistical analysis: Ordinary one-way
ANOVA followed by Tukey's multiple comparisons test (a-e) or Kruskal-Wallis test followed by Dunn's multiple comparisons test (f). * p < 0.05, * *p < 0.01 BL vs
own PT (at the same time point). AT n=6/5/5, PEG-Hboxy n=8/8/3, PEG-Hbdeoxy n= 9/5/5.
Fig. 4. Plasma levels of 8-OHdG after 7 days from transfusion. Data are shown
as mean± SD. Statistical analysis: Ordinary one-way ANOVA followed by
Tukey's multiple comparisons test.* p < 0.05 treatment groups vs AT.
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Animals were then sacriﬁced with an intraperitoneal injection of
150mg/kg pentothal sodium (Pentothal Sodium, Demas, Italy). The
heart and kidneys were quickly removed and harvested at − 80 °C for
further analysis.
2.10. Determination of residual PEG-Hbdeoxy and PEG-Hboxy in plasma
To determine the residual concentration of HBOCs, aliquots of
plasma collected before transfusion, after 2 h and after 7 days were
loaded on a 12% SDS-PAGE gel and blotted on a nitrocellulose
Fig. 5. Markers of oxidative stress in heart extracts. Content of nitrosylated proteins (a), protein HNE-adducts (b), glutathionylated proteins (c), protein MDA-
adducts (d), carbonylated proteins (e) and lipid hydroperoxides (LHP) (f) in heart extracts. Data are shown as mean± SD. Statistical analysis: Ordinary one-way
ANOVA followed by Tukey's multiple comparisons test.* p < 0.05 treatment groups vs AT.
E. Alomari et al. Free Radical Biology and Medicine 124 (2018) 299–310
304
membrane, which was then blocked with bovine serum albumin and
probed with an anti-Hb antibody conjugated with horseradish perox-
idase (HRP)(Abcam, Cambridge, UK). Upon addition of the HRP sub-
strate CheLuminate-HRP PicoDetect (PanReac AppliChem, Darmstadt,
Germany), the chemiluminescence signals were collected with a
ChemiDoc™ system (Bio-Rad Laboratories, Inc., Hercules, California,
U.S.A.).
2.11. Plasma biochemical analysis
All plasma analytes, except for L-lactate, high sensitivity cardiac
troponin T (cTnT), 8-hydroxy-2'-deoxyguanosine (8-OHdG) and allan-
toin were measured with a Roche Cobas INTEGRA 400 analyzer, using
commercial reagents provided by Roche Diagnostics (Mannheim,
Germany). For lactate dehydrogenase (LDH), PEG-Hboxy and PEG-
Hbdeoxy solutions were preliminarily tested for LDH activity to rule out
a contribution from human LDH as a contaminant. Brieﬂy, samples of
plasma, PEG-Hboxy solutions and PEG-Hbdeoxy solutions at various di-
lutions in a 10mM phosphate buﬀer, pH 7.4 were added of 10mM
NAD+ (lithium salt) and 10mML-lactate. NADH formation was mon-
itored at 340 nm using a Cary 4000 UV–VIS spectrophotometer (Agilent
Technologies, Santa Clara, CA, USA). L-lactate levels were measured
through its complete oxidation to pyruvate by lactate dehydrogenase in
the presence of hydrazine, with equimolar reduction of NAD+ to
NADH, monitored at 340 nm. Plasma hs-cTnT levels were assessed with
an electrochemiluminescence assay (ECLIA, Elecsys 2010 analyzer,
Roche Diagnostics, Germany). 8-OHdG plasma levels were assessed
with an ELISA assay (DNA Damage ELISA Kit - 8-OHdG Quantitation,
Cell Biolabs, San Diego, CA, USA) in accordance with the manufac-
turer's instructions. Allantoin, a biomarker of oxidative stress [43] was
measured using a ﬂuorimetric assay based on the enzymatic conversion
of S-allantoin to allantoate, followed by acid hydrolysis into glyoxylate
in the presence of resorcinol [44].
2.12. Proteins extraction
Individual ﬂash-frozen hearts and kidneys were thawed in ice, ex-
tensively rinsed in deionized water, weighed, frozen in liquid nitrogen
and cryogenically ground with mortar and pestle. Aliquots of the frozen
powders were stored at −80 °C for protein extraction. Powder aliquots
of 50 mg were thawed and homogenized by sonication in a buﬀered
solution containing 50mM phosphate buﬀer, pH 7.4, 1% DTT and a
protease inhibitor cocktail mixture (Sigma-Aldrich, St. Louis, MO,
USA). Finally, the homogenate was centrifuged at 15000g at 4 °C for
20min. The supernatant was collected and divided into aliquots for
analysis. The total protein content of the extracts was assessed using the
Bradford assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and was
around 1.2 ± 0.3mg/mL.
2.13. Protein and lipid oxidation of heart and kidney tissue
ELISA assays were carried out in 96-wells plates and the reactions,
either chromogenic or ﬂuorogenic, were detected using a plate reader
(either a Halo LED 96 - Dynamica Scientiﬁc Ltd., Newton Pagnell, UK or
a Tecan Spark 10M, Tecan, Zürich, Switzerland). Electroblotting of
SDS-PAGE gels on either nitrocellulose or polyvinylidene ﬂuoride
membranes was carried out with a Trans-Blot Turbo Blotting System
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). For detection, Western
blotting membranes were incubated overnight at 4 °C in blocking buﬀer
(2% BSA) and then probed with antibodies or avidin conjugates as
speciﬁed for each measurement. Absorption spectra were collected with
a Cary 4000 UV–VIS spectrophotometer (Agilent Technologies, Santa
Clara, CA, USA). All measurements were carried out at least in three
independent technical replicates for all the biological samples avail-
able. The methods used for the detection of each marker are detailed as
Supplementary Materials. For protein carbonylation, four diﬀerent de-
tection methods were preliminarily tested and compared (Alomari
et al., data in brief).
2.14. Image analysis
High-resolution images of the Coomassie-stained SDS-PAGE gel and
of Western blots were collected using a ChemiDoc™ system (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) and analyzed with the Image
Lab™ software (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The
signal of lanes or individual bands of Western blots (expressed as ar-
bitrary units) were divided by the total protein content of the corre-
sponding lane, as quantiﬁed by densitometry of the SDS-PAGE gel. For
each application, at least three technical replicates were performed.
2.15. Statistical analysis
Statistically signiﬁcant changes were assessed, as appropriate de-
pending on the data, by one-way analysis of variance (ANOVA),
Kruskal-Wallis test or two-way ANOVA, follow by Tukey's Test, Dunn's
test or Sidak's test, respectively. In all analyses, a value p < 0.05 was
Fig. 6. Antioxidant enzymes in heart extracts. Concentrations of catalase (a), SOD (b) and hydrogen peroxide (c) in heart extracts. Data are shown as mean± SD.
Statistical analysis: Ordinary one-way ANOVA followed by Tukey's multiple comparisons test.* p < 0.05 vs AT; # p < 0.05 PEG-Hboxy vs PEG-Hbdeoxy.
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taken as the level of statistical signiﬁcance. In all plots, values are re-
presented as mean± standard deviation (SD), or median±
interquartile range (IQR). Parameters resulting from data regression
are represented as coeﬃcient± standard error of the regression (SE).
Graphs and statistical analyses were performed using the software
SigmaPlot (Systat Software, San Jose, CA, USA).
Fig. 7. Markers of oxidative stress in kidney extracts. Content of nitrosylated proteins (a), protein HNE-adducts (b), glutathionylated proteins (c), protein MDA-
adducts (d), carbonylated proteins (e) and lipid hydroperoxides (LHP) per mg of total protein content (f) in kidney extracts. Data are shown as mean± SD. Statistical
analysis: Ordinary one-way ANOVA followed by Tukey's multiple comparisons test.* p < 0.05 treatment groups vs AT. ♯ vs other treatment group.
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3. Results and discussion
3.1. HBOCs preparation
HbA, PEG-Hbdeoxy and PEG-Hboxy oxygen aﬃnity and cooperativity
in the absence and presence of 200mM chloride ions and 5% carbon
dioxide are summarized in Table 1. The PEGylation yield was assessed
by densitometric analysis of SDS-PAGE gels, followed by combinatorial
calculations, as already described [27,28]. The analysis yielded a PEG/
tetramer ratio of 5.7 for PEG-Hbdeoxy and 6.6 for PEG-Hboxy (Table 1).
The endotoxin concentration for each preparation is also reported in
Table 1. The PEG-Hbdeoxy sample contained 21 EU/mL of endotoxin
(spike recovery 55%) and PEG-Hboxy contained 14 EU/mL (spike re-
covery 50%). The spike recovery values accepted by Pharmacopeia
range from 50% to 200%.
3.2. Survival after transfusion
Seven days after blood transfusion, the survival rate was 71.4% (5/
7) in the auto-transfusion group, 37.5% (3/8) in the PEG-Hboxy group
and 66.7% (6/9) in the PEG-Hbdeoxy group (Table 2). These diﬀerences
were not statistically signiﬁcant (Fig. 1S, Supplementary Materials).
3.3. Hemodynamics
Heart rate in the PEG-Hbdeoxy and PEG-Hboxy groups was higher
than in the control group during and after transfusion, respectively
(Fig. 1a and Table 2). In the PEG-Hbdeoxy group, a trend towards a
decrease in heart rate, within the physiological range, was observed
after the end of the transfusion (Fig. 1a and Table 2). An increase in
mean arterial pressure in both treatment groups, compared to the auto-
transfusion, was detected 60min after the end of the transfusion
(Fig. 1b and Table 2).
3.4. Blood gas-analysis
Both PEG-Hboxy and PEG-Hbdeoxy groups showed a decrease in Hb
and Hct levels 2 h after the end of the transfusion compared to their
own baseline and to the control group (Fig. 1c and d). Both results were
expected considering that around 26% of the animal blood was sub-
stituted with a HBOC solution, based on our calculation developed for
isovolemic gradient generation [27]. Despite the loss in RBCs, a mod-
erate increase in sO2 levels compared to baseline was observed in the
treatment groups, indicating that the two HBOCs managed to maintain,
and possibly slightly increase, sO2 levels (Fig. 1e and Table 2). Trans-
fusion with PEG-Hboxy and PEG-Hbdeoxy did not aﬀect pCO2, HCO3- and
pH levels (Table 2).
3.5. HBOCs content in plasma
The presence of HBOCs was measured in plasma pools of all animals
within each group after 2 h and after 7 days by Western blot, using an
HRP-conjugated anti-HbA monoclonal antibody (Fig. 2). The major
band at around 25 kDa, corresponding to mono-PEGylated Hb subunits,
was evaluated in a semi-quantitative fashion through densitometric
analysis (data not shown). After 7 days, plasma PEG-Hboxy and PEG-
Hbdeoxy were 13% and 4% of the amount measured after 2 h from
transfusion, respectively. The Western blot of plasma samples with-
drawn before treatment showed that the anti-Hb monoclonal antibody
did not cross-react with any Guinea pig plasma protein nor with its free
hemoglobin (Fig. 2).
3.6. Biochemical analysis of plasma
Biochemical analytes were measured in plasma samples withdrawn
before transfusion, after 2 h from transfusion and after 7 days. The le-
vels of selected analytes are reported in Fig. 3. The whole panel of
analytes is reported in Table 1S (Supplementary Materials).
L-lactate plasma concentration markedly decreased in PEG-Hboxy
animals, both after 2 h and after 7 days from transfusion, whereas it
remained unchanged in the control group and in animals treated with
PEG-Hbdeoxy (Fig. 3a). L-lactate plasma reduction is usually associated
to increased oxygen delivery to tissues and reduction of their anaerobic
metabolism. This result seems to be correlated with the previous ob-
servation that MP4 - a bioequivalent of PEG-Hboxy - delivers oxygen
mostly at the capillary level rather than in the arterioles, unlike the low
aﬃnity HBOC PolyBvHb, thus producing higher peripheral oxygenation
[35]. Indeed, for the ﬁrst time and by using two chemically similar
products, we correlated the levels of L-lactate, a marker of hyperox-
ygenation of tissues, with the oxygen aﬃnity of HBOCs. It remains to be
established if this metabolic shift toward aerobic metabolism translates
into higher oxidative stress.
Biomarkers associated with renal function, including creatinine and
urea, showed a general increase after 7 days for all treatment groups,
with diﬀerences reaching statistical signiﬁcance only in the group
treated with PEG-Hboxy (Fig. 3b and c). Overall, these results suggested
Fig. 8. Antioxidant enzymes in kidney extracts. Concentrations of hydrogen peroxide (a) and SOD (b) in kidney extracts. Data are shown as mean± SD. Statistical
analysis: Ordinary one-way ANOVA followed by Tukey's multiple comparisons test.* p < 0.05 treatment groups vs AT; # p < 0.05 PEG-Hboxy vs PEG-Hbdeoxy.
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a diminished renal function, prompting the investigation of oxidative
stress markers in this organ (vide infra).
Biomarkers of heart function were also investigated. LDH activity, a
late marker of heart damage, was measured after ruling out any LDH
activity in the HBOCs transfused solutions, which might result from
human LDH contamination in the starting material (data not shown).
LDH activity exhibited a 10-fold increase after 2 h for both groups
treated with HBOCs, but not in the auto-transfusion group, and re-
mained elevated after 7 days (Fig. 3d). LDH activity in the plasma of
animals treated with PEG-Hboxy was signiﬁcantly higher than that of
animals treated with PEG-Hbdeoxy, suggesting higher cardiac damage.
GOT showed a statistically signiﬁcant increase after 2 h - within phy-
siological ranges - only in the HBOC-transfused groups (Fig. 3e). GPT
did not exhibit any changes (Table 1S, Supplementary materials),
suggesting that GOT had myocardial origin. Creatine kinase, also a
marker of myocardial damage, slightly increased for all groups after
2 h, but was within normal ranges after 7 days (Table 1S,
Supplementary materials).
To further assess a possible heart tissue damage, plasma levels of hs-
cTnT were measured and showed increased levels after 2 h in animals
transfused with HBOCs, reaching statistical signiﬁcance only in the
group treated with PEG-Hbdeoxy (Fig. 3f). After 7 days, cTnT levels were
back to normal. cTnT is known to be transiently increased as a con-
sequence of ischemia–reperfusion injury, a tissue damage produced
when blood supply returns to the tissue after a period of ischemia but
also in non-ischemic conditions [45]. In the latter condition, cTnT le-
vels are usually correlated with tachycardia, in agreement with the
observed cardiac parameters (Fig. 1a).
3.7. Oxidation markers in plasma
8-OHdG is a DNA-derived marker of oxidative stress. Its elevated
levels in brain preparations of Guinea pig were reported upon trans-
fusion with cell-free hemoglobin to evaluate its eﬀects on the brain
blood barrier integrity [42]. 8-OHdG plasma concentration was com-
pared for the three groups of animals after 7 days from transfusion.
Plasma levels were three-fold higher in both PEG-Hboxy and PEG-
Hbdeoxy groups in comparison with the auto-transfused group (Fig. 4).
The diﬀerences between the groups treated with PEG-Hboxy and PEG-
Hbdeoxy were not statistically signiﬁcant, although PEG-Hboxy appeared
associated to a slightly higher 8-OHdG plasma concentration.
Allantoin increased after 2 h in all groups, indicating an increased
non-enzymatic urate oxidation to allantoin as a response to procedure,
but returned to basal levels after 7 days (Table 1S, Supplementary
materials). Non-enzymatic conversion of urate into allantoin constitutes
an eﬃcient antioxidant system, accounting for 65% of the total free
radical scavenging capacity of the human plasma [46]. Urate levels in
humans are much higher (around 300 μM) than in Guinea pigs, since
urate cannot be enzymatically degraded in hominoids due to the loss by
pseudogenization of the enzymatic pathway for oxidative uricolysis
[47,48]. Guinea pigs have lost the endogenous capacity of producing
the plasmatic antioxidant ascorbate, but maintained a functional ur-
icolytic pathway. Therefore, they lack most of the circulating urate
available for the scavenging of oxidant species, suggesting that, at least
at plasmatic levels, this animal model is more sensitive than humans in
respect to circulating oxidant agents.
3.8. Oxidation markers in heart proteins and lipids
Markers of heart protein oxidation and lipid peroxidation are re-
ported in Fig. 5. Neither S-glutathionylation, S-nitrosylation, carbony-
lation nor MDA adducts showed any diﬀerence between the three
groups (Fig. 5c, a, e, d). Also LPH content did not exhibit any statisti-
cally signiﬁcant diﬀerence between the groups (Fig. 5f). However,
protein adducts with HNE were three-fold higher in both groups of
HBOCs-transfused animals in comparison with the auto-transfusion
group (Fig. 5b). PEG-Hboxy appeared to produce a higher elevation in
comparison to PEG-Hbdeoxy, without reaching statistical signiﬁcance.
HNE adducts were already identiﬁed as markers of oxidative stress in
the brain of Guinea pigs treated with cell-free hemoglobin [42]. Here,
we show that altered levels are detectable in the heart tissue at least for
a week after treatment. Among the protein adducts associated to oxi-
dative stress, HNE adducts appeared to be the only relevant markers to
assess diﬀerences between HBOC and auto-transfusion in the cardiac
tissue.
3.9. Catalase, SOD, hydrogen peroxide in heart extracts
Hydrogen peroxide and the antioxidant enzymes catalase and SOD
(as total SOD activity) were measured in heart extracts (Fig. 6).
Whereas SOD did not exhibit any diﬀerence between groups (Fig. 6b),
catalase and hydrogen peroxide were signiﬁcantly lower in the group
treated with PEG-Hbdeoxy in comparison with the other two (Fig. 6a and
c). The decrease in catalase activity might be associated to a ROS-
mediated down-regulation of the expression of the enzyme under oxi-
dative stress, as observed in hepatocellular carcinoma [49]. A transient
decrease of catalase was also observed in Guinea pigs treated with the
polymerized bovine Hb Oxyglobin [39]. It remains to be understood the
reason of the signiﬁcant decrease in catalase upon treatment with PEG-
Hbdeoxy in comparison with PEG-Hboxy.
3.10. Oxidation markers in kidney proteins and lipids
Markers of kidney protein oxidation and lipid peroxidation are re-
ported in Fig. 7. Neither S-nitrosylation (Fig. 7a), S-glutathionylation
(Fig. 7c), carbonylation adducts (Fig. 7e) or LHP content (Fig. 7f)
showed any diﬀerence between the three groups. Protein adducts with
HNE were signiﬁcantly higher in both groups of HBOCs-transfused
animals in comparison with the auto-transfusion group, with a four-fold
diﬀerence for PEG-Hboxy-treated animals (Fig. 7b), the only group ex-
hibiting a statistically signiﬁcant diﬀerence in comparison with the
auto-transfusion group. Additionally, unlike in the heart tissue, also the
MDA adducts exhibited a signiﬁcantly higher level for PEG-Hboxy-
treated animals (Fig. 7d), but not for PEG-Hbdeoxy-treated animals,
possibly indicating a higher kidney toxicity for the former, that contains
a much higher concentration of dimers in comparison to PEG-Hbdeoxy
and is therefore more prone to renal ﬁltration.
3.11. Catalase, SOD and hydrogen peroxide in renal extracts
Hydrogen peroxide and the antioxidant enzymes catalase and SOD
(as total SOD activity) were measured in kidney extracts (Fig. 8a and b).
Unlike for heart extracts, no signiﬁcant diﬀerence was observed within
groups. Catalase activity could not be measured because of the strong
interference with the heme content of the kidney extract.
4. Conclusions
An exchange transfusion model in Guinea pig was designed to
evaluate the oxidative stress induced by two hemoglobin-based oxygen
carriers (HBOCs) modiﬁed with the same PEGylation chemistry but
endowed with diﬀerent oxygen binding properties. The concentration
of HBOCs was reduced by around 90% in plasma after 7 days from
transfusion. L-lactate decrease in PEG-Hboxy animals conﬁrmed the
capacity of high-aﬃnity HBOCs to increase oxygen partial pressure at
the capillary level. Increased creatinine and urea levels pointed to a
decreased renal function, whereas markers of heart damage – LDH,
creatine kinase and troponin – indicated at least transient cardiac
toxicity. These results prompted the evaluation of markers of protein,
DNA and lipid oxidation in the plasma, in the heart and in kidneys. Both
HBOCs produced a signiﬁcant increase in 4-hydroxynonenal adducts in
heart and kidney extracts and of 8-oxo-2'-deoxyguanosine in plasma,
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suggesting that these analytes could constitute a platform to evaluate
HBOCs-induced oxidative stress. Malondialdehyde adducts increased
only in the kidneys of animals treated with PEG-Hboxy suggesting – in
conjunction with a similar trend for creatinine and urea - a higher renal
oxidative toxicity in comparison to PEG-Hbdeoxy, endowed with lower
oxygen aﬃnity. Overall, these results indicate that the oxygen binding
properties of HBOCs play a signiﬁcant role in modulating the degree of
oxidative stress.
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